Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
156.60    3.80 (2.49%)
Bid:
156.40
Ask:
156.80
Spread: 0.40 (0.256%)
Market Cap: £896.25m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

AGM / Interim Management Statement

22 Apr 2015 07:00

ELEMENTIS PLC - AGM / Interim Management Statement

ELEMENTIS PLC - AGM / Interim Management Statement

PR Newswire

London, April 21

22 April 2015 Elementis plc - AGM / Interim Management Statement Elementis plc (ELM.L, the "Company" or the "Group"), the Global SpecialtyChemicals Company, today issues its Interim Management Statement for the threemonths ended 31 March 2015. Commenting on the Company's performance Group Chief Executive, David Dutro,said: "Despite subdued global economic activity,the Elementis team hasdelivered encouraging results in the first quarter of 2015 and we remainconfident in the Group's prospects for the coming year. Moving forward ourstrategy is clear and focused on delivering long-term shareholder value. Weremain resolute in our commitment to outperform our competitors by providinginnovative products and solutions that make our customers more successful. Wehave continued to invest in the future growth of our Specialty Productsbusiness andalthough we are currently in the phase of absorbing the additionalrelated costs,these investmentsare the building blocks of an exciting future". CurrencyConsistent with the Group's Final Results statement in February this year,currency movements reduced Group sales for the first quarter by 5 per centcompared to the same period last year, however, operating profit was impactedby less than 1 per cent, assisted by the Group's hedging programme. In order toprovide a clearer understanding of the Group's underlying performance thefollowing business commentaries focus on constant currency sales ("CC sales"). In Specialty Products, CC sales in the first quarter were 3 per cent higherthan the same period last year and operating margins improved by 50 basispoints, assisted by currency movements. * In coatings additives, CC sales in North America were 4 per cent higher than the previous year, with good growth in decorative coatings as a result of new innovative products from the recently commissioned facility in New Martinsville. Sales in Latin America were 9 per cent higher as the business continued to successfully expand sales outside of Brazil. Sales in Asia Pacific were 5 per cent higher, benefiting from ongoing market share gains in China and good progress in other countries. In Europe, despite relatively subdued economic activity, sales grew by 5 per cent due to new product launches in decorative applications and market share gains. * In personal care, CC sales were 6 per cent higher than the same period last year with good growth in North America, Asia Pacific and Latin America. The business team continues to successfully expand the business both geographically and through new product introductions. * As anticipated, CC sales in oilfield were 13 per cent lower than the first quarter of 2014, as lower oil prices impacted on drilling activity across most of the customer base. In Chromium, there was no significant currency translation impact on sales andoperating profit. Sales volumes in the first quarter were 7 per cent lower thanthe same period last year as demand for refractory grade chrome oxide, whichwas particularly strong in 2014, returned to more normal levels following thecompletion of a number of significant customer projects. Otherwise sales inleather tanning and timber treatment continued to show good growth. Fixed costsin the period benefited from plant optimisation activities and the positiveresolution of some legacy issues. While markets outside of North Americacontinue to be challenging, management expects a full year result that is inline with the business's stated strategy of "stable earnings and cash flow". The Group's balance sheet remains strong and is expected to be in a net cashposition at the end of the year which, under our current special dividendpolicy, will continue to provide shareholders with attractive returns. ENDS Enquiries: Elementis + 44 (0) 207 408 9300David Dutro, Chief ExecutiveBrian Taylorson, Finance Director FTI Consulting + 44 (0) 203 727 1000Deborah ScottMatthew Cole
Date   Source Headline
8th Jun 20265:14 pmRNSTransaction in Own Shares
3rd Jun 20267:00 amRNSCommencement of share buyback programme
2nd Jun 20267:00 amRNSSale of Pharma business & intended buyback launch
1st Jun 20269:58 amRNSTotal Voting Rights
5th May 20265:26 pmRNSHolding(s) in Company
1st May 20269:59 amRNSTotal Voting Rights
29th Apr 20263:47 pmRNSResult of AGM
29th Apr 20267:00 amRNSFirst quarter trading update
8th Apr 20264:14 pmRNSDirector/PDMR Shareholding
7th Apr 20263:06 pmRNSDirector/PDMR Shareholding
1st Apr 202610:18 amRNSTotal Voting Rights
30th Mar 20265:06 pmRNSCorrection - Admission to Trading
30th Mar 20261:58 pmRNSAdmission to Trading
26th Mar 202612:09 pmRNSNotice of AGM and Annual Report & Accounts
19th Mar 20267:00 amRNSDirectorate change
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:39 pmRNSDirector/PDMR Shareholding
9th Mar 20265:14 pmRNSHolding(s) in Company
5th Mar 20265:11 pmRNSBlocklisting Interim Review
5th Mar 20264:57 pmRNSPreliminary Results - Correction
5th Mar 20267:00 amRNSPreliminary Results
2nd Mar 202610:00 amRNSTotal Voting Rights
25th Feb 20264:22 pmRNSDirectorate change
2nd Feb 202610:05 amRNSTotal Voting Rights
21st Jan 20267:00 amRNSTrading Update
2nd Jan 202611:10 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSConfirmation of Board changes
2nd Jan 20267:00 amRNSConfirmation of Board changes
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
15th Dec 20257:00 amRNSCompletion of Buyback programme
15th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20255:35 pmRNSTransaction in Own Shares
10th Dec 20256:12 pmRNSTransaction in Own Shares
9th Dec 20255:55 pmRNSTransaction in Own Shares
8th Dec 20255:52 pmRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20256:06 pmRNSTransaction in Own Shares
3rd Dec 20255:28 pmRNSTransaction in Own Shares
3rd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20255:49 pmRNSTransaction in Own Shares
28th Nov 20255:49 pmRNSTransaction in Own Shares
27th Nov 20255:40 pmRNSTransaction in Own Shares
27th Nov 20257:00 amRNSTransaction in Own Shares
26th Nov 20257:00 amRNSElementis acquires personal care specialist
25th Nov 20255:44 pmRNSTransaction in Own Shares
24th Nov 20256:01 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.